

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

26 May 2026

### Comparison of the effect of Nigella sativa oil and placebo supplementation on flow mediated dilation (FMD) and vascular inflammatory biomarkers in subjects with cardiovascular disease risk factors

#### Protocol summary

##### Study aim

This clinical trial aims to assess the effect of Nigella sativa oil on flow mediated dilation (FMD) and vascular inflammatory biomarkers in subject with cardiovascular disease risk factors

##### Design

A single center, randomized, single blinded, controlled clinical trial with a parallel group design and 50 participants evaluating the effect of Nigella sativa oil on vascular function. Stratified block randomization will be employed to assign subject to each of the two groups.

##### Settings and conduct

Fifty patients with at least one cardiovascular risk factor, referred to Imam Reza (AS) Hospital, will be randomized into two groups, Nigella sativa oil (2 capsules of 500 mg per day) or mineral oil (2 capsules of 500 mg per day) for 8 weeks. Flow mediated dilation and plasma levels of ICAM-1 and VCAM-1 are measured at baseline and after 8 weeks. Patients did not know the type of intervention and the study was single blind.

##### Participants/Inclusion and exclusion criteria

Inclusion Criteria: Willingness to participate in the study; Age between 20-75 years; Having elevated at least one of cardiovascular disease risk factors( including Dyslipidemia or diabetes mellitus or hypertension or smoking). Exclusion Criteria: Unwillingness to continue participation; BMI> 30; Patients on anticoagulant or nitrates drugs; Consumption of vitamins or minerals supplements during past month; Chronic kidney disease stage 4 or 5, pregnancy.

##### Intervention groups

Intervention group: receiving 2 capsules of 500 mg Nigella sativa oil daily for 8 weeks. Control group: receiving 2 capsules of 500 mg mineral oil daily for 8 weeks.

##### Main outcome variables

Flow mediated dilation (FMD); ICAM-1 and VCAM-1 inflammatory factors

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20201126049495N1**

Registration date: **2020-12-10, 1399/09/20**

Registration timing: **prospective**

Last update: **2020-12-10, 1399/09/20**

Update count: **0**

##### Registration date

2020-12-10, 1399/09/20

##### Registrant information

##### Name

Hadi Emamat

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 5545 0314

##### Email address

hadiemamat@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-12-21, 1399/10/01

##### Expected recruitment end date

2021-03-19, 1399/12/29

##### Actual recruitment start date

empty

**Actual recruitment end date**  
empty

**Trial completion date**  
empty

**Scientific title**  
Comparison of the effect of Nigella sativa oil and placebo supplementation on flow mediated dilation (FMD) and vascular inflammatory biomarkers in subjects with cardiovascular disease risk factors

**Public title**  
The effect of Nigella sativa oil on vascular function

**Purpose**  
Prevention

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Willingness to participate in the study Age between 20-75 years Having at least one of cardiovascular disease risk factors (including diabetes, dyslipidemia, hypertension, smoking )  
**Exclusion criteria:**  
having BMI>30 Patients on nitrate or anticoagulant drugs Regular consumption (more than once in a week) of vitamins or minerals supplements during past month Chronic kidney disease stage 4 or 5 pregnancy

**Age**  
From **20 years** old to **75 years** old

**Gender**  
Both

**Phase**  
N/A

**Groups that have been masked**  

- Participant

**Sample size**  
Target sample size: **50**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
Eligible participants will be randomly assigned, in a ratio of 1:1, to either Nigella sativa group or placebo group for 8 weeks. Stratified block randomization will be employed to assign subject to each of the two groups. Stratification subdivides patients into those with diabetes or without diabetes and in each stratum, block size of 4-6 will be used with a 1:1 randomization between the two groups in each block, i.e. each block will consist of 2-3 subjects for the intervention group and 2-3 subjects for the placebo group. the predetermined allocation sequence of each block will be based on a computer-generated randomization list. An online program will be used for this purpose (www.randomizer.org). For each stratum, 8 blocks of 4 to 6 will considered and the sequence of patients in each block will be determined using software. Half of numbers in each block will be for the nigella sativa group and the other half for the placebo group.

**Blinding (investigator's opinion)**  
Single blinded

**Blinding description**  
Patients are blinded of the type of supplement they are

consuming, but the main investigator who assigns patients to intervention or placebo groups is not blinded. Nigella sativa oil and placebo supplements are given to patients in similar capsules.

**Placebo**  
Used

**Assignment**  
Parallel

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of the Islamic Republic of Iran Army University of Medical Sciences

##### Street address

The Islamic Republic of Iran Army University of Medical Sciences, Etemadzadeh street, West Fatemi street, Tehran

##### City

Tehran

##### Province

Tehran

##### Postal code

1411718541

##### Approval date

2020-11-18, 1399/08/28

##### Ethics committee reference number

IR.AJAUMS.REC.1399.167

## Health conditions studied

### 1

#### Description of health condition studied

Cardiovascular disease, Hypertension, diabetes, dyslipidemia

##### ICD-10 code

R94.30

##### ICD-10 code description

Abnormal result of cardiovascular function study, unspecified

## Primary outcomes

### 1

#### Description

Flow mediated dilation (FMD)

#### Timepoint

Baseline and the end of the study

#### Method of measurement

sonography

## Secondary outcomes

### 1

#### Description

plasma ICAM-1

#### Timepoint

Baseline and the end of the study

#### Method of measurement

ELISA

### 2

#### Description

Plasma VCAM-1

#### Timepoint

Baseline and the end of the study

#### Method of measurement

ELISA

## Intervention groups

### 1

#### Description

Intervention group: Daily consumption of 2 capsules of 500 mg Nigella sativa oil for 8 weeks.

#### Category

Treatment - Other

### 2

#### Description

Control group: Daily consumption of 2 capsules of 500 mg mineral oil for 8 weeks.

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

The Islamic Republic of Iran Army University of Medical Sciences

##### Full name of responsible person

Said Hadi

##### Street address

The Islamic Republic of Iran Army University of Medical Sciences, Etemadzadeh street, West Fatemi street, Tehran

##### City

Tehran

##### Province

Tehran

##### Postal code

1411718541

##### Phone

+98 21 4382 2284

##### Email

s.hadinu@yahoo.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Artesh University of Medical Sciences

##### Full name of responsible person

Sanaz Zargar Balaye Jame

##### Street address

address The Islamic Republic of Iran Army University of Medical Sciences, Etemadzadeh street, West Fatemi street, Tehran

##### City

Tehran

##### Province

Tehran

##### Postal code

1411718541

##### Phone

+98 21 8609 6350

##### Email

s.hadinu@yahoo.com

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

No

#### Title of funding source

Vice-Chancellor for Research, The Islamic Republic of Iran Army University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Artesh University of Medical Sciences

##### Full name of responsible person

Said Hadi

##### Position

Assistant Professor

##### Latest degree

Master

##### Other areas of specialty/work

Nutrition

##### Street address

The Islamic Republic of Iran Army University of Medical Sciences, Etemadzadeh street, West Fatemi street, Tehran

##### City

Tehran

**Province**  
Tehran  
**Postal code**  
1411718541  
**Phone**  
+98 21 4382 2284  
**Fax**  
**Email**  
s.hadinu@yahoo.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Artesh University of Medical Sciences  
**Full name of responsible person**  
Said Hadi  
**Position**  
Assistant Professor  
**Latest degree**  
Master  
**Other areas of specialty/work**  
Nutrition  
**Street address**  
The Islamic Republic of Iran Army University of Medical Sciences, Etemadzadeh street, West Fatemi street, Tehran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1411718541  
**Phone**  
+98 21 4382 2284  
**Fax**  
**Email**  
s.hadinu@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Artesh University of Medical Sciences  
**Full name of responsible person**  
Said Hadi  
**Position**  
Assistant Professor  
**Latest degree**  
Master  
**Other areas of specialty/work**  
Nutrition  
**Street address**  
The Islamic Republic of Iran Army University of Medical Sciences, Etemadzadeh street, West Fatemi street, Tehran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1411718541  
**Phone**  
+98 21 4382 2284  
**Fax**  
**Email**  
s.hadinu@yahoo.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

### Justification/reason for indecision/not sharing IPD

There is no further information.

### Study Protocol

No - There is not a plan to make this available

### Statistical Analysis Plan

No - There is not a plan to make this available

### Informed Consent Form

No - There is not a plan to make this available

### Clinical Study Report

No - There is not a plan to make this available

### Analytic Code

No - There is not a plan to make this available

### Data Dictionary

No - There is not a plan to make this available